AI-generated · Based on company filings and platform data · Not investment advice
Pfizer (PFE) Q3 2026 Earnings Brief: Revenue $16.58B, −0.4% YoY
Released Nov 3, 2026 (ET)
Quarter: Q3 2026, period ended 2026-09-30; released 2026-11-03 (ET).
In one line: Pfizer's revenue in the third quarter of 2026 was US$16.58 billion, with adjusted EPS of US$0.87 exceeding analysts' consensus estimate of US$0.74, and year-on-year revenue was basically the same.
Key numbers
| Metric | This quarter | Note |
|---|---|---|
| Revenue | $16.58B | YoY −0.4% |
| Adj. EPS vs consensus | $0.87 vs $0.74 | Beat (+18.3%) |
| GAAP diluted EPS | $0.56 | Different basis from consensus |
| Net margin | 19.6% | Net income $3.24B |
| Next-quarter EPS consensus | $0.69 | 18 analysts; revenue consensus $17.22B |
Three things to know
1. Cost optimization plan advances
The company said it announced approximately $1 billion in new net cost savings in the third quarter of 2026, resulting from technology and process simplification in commercial, R&D and support functions, and is expected to be gradually realized from 2027 to 2029. Relevant one-time expenditures are expected to reach US$2 billion and will be completed by 2029.
2. Manufacturing optimization leads to long-term savings
The company has launched the next phase of its manufacturing optimization plan, which is expected to bring approximately US$1.5 billion in additional cost savings from 2027 to 2029, mainly through network structure adjustment, product portfolio optimization and operational efficiency improvements. One-time costs to achieve this goal are expected to be $4 billion, of which approximately 60% will be non-cash expenses.
3. Core product revenue growth offsets decline in epidemic products
Total revenue for the quarter fell 0.4% year-on-year, but after excluding the new crown products Comirnaty and Paxlovid, operating income increased 7% year-on-year. Growth mainly comes from products such as Eliquis, Padcev, Vyndaqel series, Nurtec ODT/Vydura and Lorbrena.
Market reaction
Results were released on 2026-11-03 (ET). From the last pre-report close (2026-11-02, $30.23) to the close of the first session after the report (2026-11-04, $30.35), the stock moved +0.39%. The report-day close was $29.57; the next session closed +2.63% from it (for after-hours releases, this leg better reflects the reaction to the report).
What to watch next
- Pay attention to the reflection of cost savings in the fourth quarter financial report of 2027.
- Observe the actual progress of one-time expenditures related to manufacturing optimization projects from 2027 to 2029.
- Watch for further explanation from management on the sustainability of growth in the non-COVID-19 product line in subsequent reports.
- Next report date (platform calendar): 2027-02-02
Sources
- Financials: fundamentals-svc (EDGAR filings, analyst consensus)
- Prices: fundamentals-svc /v1/candles-ondemand
- MD&A source: 10-Q (filed 2026-11-03)
- Company press release (8-K): SEC EDGAR